Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Pseudomonas Lung Infections in Cystic Fibrosis

Dorene F. Balmer, Joan I. Schall, Virginia A. Stallings

Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis Stefanie Hennig, Karen McKay, Suzanna Vidmar, Katie O'Brien,

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis,

Inhaled antibiotic therapy: What drug. What dose. What regimen

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Development of selective media for the isolation of yeasts and filamentous fungi from the sputum of adult patients with cystic fibrosis (CF) Yuriko Nagano,

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Pulmonary exacerbations in CF patients with early lung disease

The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population Brandie D. Wagner, Frank J. Accurso,

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

The Journal of Cystic Fibrosis: Sunny perspectives

Laurent Vecellio, Mohamed E

A.H. Gifford Journal of Cystic Fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Cystic fibrosis related diabetes in an extremely young patient

Physiologic endpoints for clinical studies for cystic fibrosis

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration Drucy Borowitz, Daniel Gelfond, Karen.

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

Valerie Waters, Eshetu G

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas.

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby,

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Antine E. Stenbit, Wendy M. Bullington, Julie L. Heh, Patrick A. Flume

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Eradication of early P. aeruginosa infection in children

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis Kavi J. Littlewood, Kyoko Higashi,

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

CFTR modulators and pregnancy: Our work has only just begun

Patient segregation and aggressive antibiotic eradication therapy can control methicillin- resistant Staphylococcus aureus at large cystic fibrosis centres

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity Henry J. Legere, Ross I. Palis, Tito Rodriguez.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: A review Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi Journal of Cystic Fibrosis Volume 8, Issue 6, Pages 361-369 (December 2009) DOI: 10.1016/j.jcf.2009.08.004 Copyright © 2009 Elsevier B.V. Terms and Conditions

Fig. 1 The rationale of using inhaled tobramycin: mean sputum tobramycin concentrations after intravenous tobramycin 80mg/m2 three times daily (approximately 6–10.8mg/kg/day) for 18–21days in four patients with CF [71] and after inhaled tobramycin 300mg/5ml twice daily with PARI LC Plus for three 28-day on/28-day off treatment cycles in 247 patients with CF [72]. Journal of Cystic Fibrosis 2009 8, 361-369DOI: (10.1016/j.jcf.2009.08.004) Copyright © 2009 Elsevier B.V. Terms and Conditions